sana vereceğim kaynakçaları apa formatına uygun olup olmadığını kontrol et. sonra ise bunları Soyadlarına göre alfabetik olacak şekilde sıralayarak tekrar yaz lütfen.
işte kaynakça: 
•	Gale SA, Acar D, Daffner KR. 2018. Dementia. American Journal of Medicine 131:1161–9. [PubMed] [Google Scholar]
•	Scheltens P, Blennow K, Breteler MMB, et al. 2016. Alzheimer's disease. The Lancet 388:505–17. [PubMed] [Google Scholar]
•	Joe E, Ringman JM. 2019. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. British Medical Journal (BMJ) 367:l6217. [PubMed] [Google Scholar]
•	Kim J, Jeong M, Stiles WR, Choi HS. 2022. Neuroimaging modalities in Alzheimer's disease: diagnosis and clinical features. International Journal of Molecular Sciences 23:6079. [PMC free article] [PubMed] [Google Scholar]
•	Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. 2021. Diagnosis of early Alzheimer's disease: clinical practice in 2021. Journal of Prevention of Alzheimer's Disease 8:371–86. [PubMed] [Google Scholar]
•	Niu H, Álvarez-Álvarez I, Guillén-Grima F, Aguinaga-Ontoso I. 2017. Prevalence and incidence of Alzheimer's disease in Europe: a meta-analysis. Neurologia 32:523–32. [PubMed] [Google Scholar]

•	Jia J, Wang F, Wei C, et al. 2014. The prevalence of dementia in urban and rural areas of China. Alzheimer's & Dementia 10:1–9. [PubMed] [Google Scholar]

•	Fiest KM, Roberts JI, Maxwell CJ, et al. 2016. The prevalence and incidence of dementia due to Alzheimer's disease: a systematic review and meta-analysis. Canadian Journal of Neurological Sciences 43:S51–82. [PubMed] [Google Scholar]

•	Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. 2013. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimer's & Dementia 9:63–75.e2.

•	Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D'Agostino RB, White LR. 1992. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 42:115-9.

•	Henderson AS. 1988. The risk factors for Alzheimer's disease: a review and a hypothesis. Acta Psychiatrica Scandinavica 78:257-275.

•	Herrup K. 2010. Reimagining Alzheimer's disease - an age-based hypothesis. Journal of Neuroscience 30:16755-16762.

•	Killin LOJ, Starr JM, Shiue IJ, Russ TC. 2016. Environmental risk factors for dementia: a systematic review. BMC Geriatrics 16:175.

•	Block ML, Elder A, Auten RL, Bilbo SD, Chen H, Chen J-C, Cory-Slechta DA, Costa D, Diaz-Sanchez D, Dorman DC. 2012. The outdoor air pollution and brain health workshop. Neurotoxicology 33:972–984.




•	Oudin A, Forsberg B, Nordin Adolfsson A, Lind N, Modig L, Nordin M, Nordin S, Adolfsson R, Nilsson LG. 2016. Traffic-Related Air Pollution and Dementia Incidence in Northern Sweden: A Longitudinal Study. Environmental Health Perspectives 124(3):306–312. [PMC free article] [PubMed]
•	Chang KH, Chang MY, Muo CH, Wu TN, Chen CY, Kao CH. 2014. Increased risk of dementia in patients exposed to nitrogen dioxide and carbon monoxide: a population-based retrospective cohort study. PLoS One 9(8):e103078. 
•	Emard JF, Andre P, Thouez JP, Mathieu J, Boily C, Beaudry M, Cholette A, Robitaille Y, Bouchard R, Daoud N, et al. 1994. Geographical distribution of Alzheimer’s disease cases at birth and the geochemical profile of Saguenay-Lac-Saint-Jean Quebec, Canada (IMAGE Project). Water Air Soil Pollution 72(1–4):251–264. 
•	Dartigues JF, Gagnon M, Michel P, Letenneur L, Commenges D, Barberger-Gateau P, Auriacombe S, Rigal B, Bedry R, Alperovitch A, et al. 1991. The Paquid research program on the epidemiology of dementia. Methods and initial results. Revue Neurologique 147(3):225–230. [PubMed] [Google Scholar]
•	Edwardson JA, Candy JM, Ince PG, McArthur FKM, Morris CM, Oakley AE, Taylor GA, Bjertness E. 1992. Aluminium accumulation, b-amyloid deposition and neurofibrillary changes in the central nervous system. Chichester: Wiley. pp. 165–185. [PubMed] [Google Scholar]
•	El-Rahman SSA. 2003. Neuropathology of aluminum toxicity in rats (glutamate and GABA impairment). Pharmacological Research 47(3):189–194. doi: 10.1016/S1043-6618(02)00336-5. [PubMed] [CrossRef] [Google Scholar]
•	Tomljenovic L. 2011. Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? Journal of Alzheimer's Disease 23(4):567–598.
•	Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. 1984. Alzheimer’s disease: a study of epidemiological aspects. Annals of Neurology 15:335–341.
•	Mortimer JA, French LR, Hutton JT, Schuman LM. 1985. Head injury as a risk factor for Alzheimer’s disease. Neurology 35:264–267.
•	Shalat SL, Seitzer B, Pidcock C, Baker EL. 1986. A case-control study of medical and family history and Alzheimer’s disease. American Journal of Epidemiology 124:540.
•	Armstrong RA. 2019. Risk factors for Alzheimer’s disease. Folia Neuropathologica 2/2019vol. 5725.
•	Hardy JA, Higgins GA. 1992. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184-5. doi: 10.1126/science.1566067. PMID: 1566067 Review.
•	Blacker D, Tanzi RE. 1998. The genetics of Alzheimer disease: current status and future prospects. Archives of Neurology 55(3):294-6. doi: 10.1001/archneur.55.3.294.
•	Sherrington R, Rogaev EI, Liang Y, et al. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375(6534):754-60. doi: 10.1038/375754a0.
•	Bertram L, Lill CM, Tanzi RE. 2010. The genetics of Alzheimer disease: back to the future. Neuron 68(2):270-81. doi: 10.1016/j.neuron.2010.10.013. PMID: 20955934.
•	Mann DM. 1988. Alzheimer's disease and Down's syndrome. Histopathology 13(2):125-37. doi: 10.1111/j.1365-2559.
•	Glenner GG, Wong CW. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochemical and Biophysical Research Communications 122(3):1131-5.
•	Mazon JN, de Mello AH, Ferreira GK, Rezin GT. 2017. The impact of obesity on neurodegenerative disease. Life Sciences 182:22-28.
•	Tolppanen AM, Ngandu T, Kareholt I, Laatikainen T, Rusanen M, Soininen H, Kivipelto M. 2014. Midlife and late-life body mass index and late-life dementia: Results from a prospective population-based cohort. Journal of Alzheimer's Disease 38:201-209.
•	Blass JP, Zemcov A. 1984. Alzheimer’s disease – a metabolic systems degeneration. Neurochemical Pathology 2:103-114.
•	Liu GY, Yao LF, Liu JF, Jiang YS, Ma GD, Chen ZG, Zhao B, Li KS. 2014. Cardiovascular disease contributes to Alzheimer’s disease: evidence from large-scale genome-wide association studies. Neurobiology of Aging 35:786-792.
•	Carbone I, Lazzarotto T, Ianni M, Porcellini E, Forti P, Masliah E, Gabrielli L, Licastro F. 2014. Herpes virus in Alzheimer’s disease: related to progression of the disease. Neurobiology of Aging 35:122-129.
•	Kirk-Sanchez NJ, McGough EL. 2014. Physical exercises and cognitive performance in the elderly: Current perspectives. Clinical Interventions in Aging 9:51-62.
•	Jonaitis E, La Rue A, Mueller KD, Koscik RL, Hermann B, Sager MA. (2013). Cognitive activities and cognitive performance in middle-aged adults at risk for Alzheimer's disease. Psychology and Aging, 28, 1004-1014.
•	Grant WB. (2014). Trends in diet and Alzheimer disease during the nutrition transition in Japan and developing countries. Journal of Alzheimer's Disease, 38, 611-620.
•	Scarmeas N, Stern Y, Sergentanis T, Psaltopoulou T. (2006). Mediterranean Diet and Alzheimer's disease. Current Alzheimer Research, 12, 736-744.
•	Engelhart M. (2002). Dietary intake of antioxidants and risk of Alzheimer Disease. Journal of the American Medical Association, 287, 3223.
•	Perl DP. (2010). Neuropathology of Alzheimer's disease. Mount Sinai Journal of Medicine, 77, 32-42.
•	Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 1.
•	Krasuski JS, Alexander GE, Horwitz B, Daly EM, Murphy DG, Rapoport SI, Schapiro MB. (1998). Volumes of medial temporal lobe structures in patients with Alzheimer's disease and mild cognitive impairment (and in healthy controls). Biological Psychiatry, 43(1), 60-8.
•	Pearlson GD, Harris GJ, Powers RE, Barta PE, Camargo EE, Chase GA, Noga JT, Tune LE. (1992). Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Archives of General Psychiatry, 49(5), 402-8.
•	Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP. (1995). Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Archives of Neurology, 52, 81-88.
•	Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42, 631-639.
•	Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 141(7), 1917-1933.
•	Chakraborty S, Lennon JC, Malkaram SA, Zeng Y, Fisher DW, Dong H. (2019). Serotonergic system, cognition, and BPSD in Alzheimer's disease. Neuroscience Letters, 704, 36-44. doi: 10.1016/j.neulet.2019.03.050.
•	James T, Kula B, Choi S, Khan SS, Bekar LK, Smith NA. (2021). Locus coeruleus in memory formation and Alzheimer's disease. European Journal of Neuroscience, 54(8), 6948-6959. doi: 10.1111/ejn.15045.
•	McKhann GM, Knopman DS, Chertkow H, et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7(3), 263-269.
•	Farlow MR, Cummings JL. (2007). Effective pharmacologic management of Alzheimer's disease. The American Journal of Medicine, 120(5), 388-397.
•	Jost BC, Grossberg GT. (1995). The natural history of Alzheimer's disease: a brain bank study. Journal of the American Geriatrics Society, 43(11), 1248-1255.
•	Jost BC, Grossberg GT. (1996). The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. Journal of the American Geriatrics Society, 44(9), 1078-1081.
•	Atri A. (2019). The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Medical Clinics of North America, 103(2), 263-293.
•	Collie A, Maruff P. (2000). The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neuroscience & Biobehavioral Reviews, 24(3), 365-374. doi: 10.1016/s0149-7634(00)00012-9.
•	Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. (2000). The preclinical phase of Alzheimer's disease: A 22-year prospective study of the Framingham Cohort. Archives of Neurology, 57(6), 808-813. doi: 10.1001/archneur.57.6.808.
•	Bayles KA. (1991). Age at onset of Alzheimer's disease. Relation to language dysfunction. Archives of Neurology, 58.

•	Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. (2021). Alzheimer's disease. The Lancet, 397(10284), 1577-1590. doi: 10.1016/S0140-6736(20)32205-4.
•	Bondi MW, Edmonds EC, Salmon DP. (2017). Alzheimer's Disease: Past, Present, and Future. Journal of the International Neuropsychological Society, 23(9-10), 818-831. doi: 10.1017/S135561771700100X.
•	Folstein MF, Folstein SE, McHugh PR. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198. doi: 10.1016/0022-3956(75)90026-6.
•	Appell J, Kertesz A, Fisman M. (1982). A study of language functioning in Alzheimer patients. Brain and Language, 17(1), 73-91. doi: 10.1016/0093-934X(82)90006-2.
•	Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. (2007). Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology, 14, 1-26.
•	Emre M. (2013). Nöroloji Temel Kitabı. Güneş Tıp Kitabevleri.
•	Babic T. (1999). The cholinergic hypothesis of Alzheimer’s disease: A review of progress. Journal of Neurology, Neurosurgery & Psychiatry, 67(5), 558.
•	Paroni G, Bisceglia P, Seripa D. (2019). Understanding the amyloid hypothesis in Alzheimer's disease. Journal of Alzheimer's Disease, 68, 493-510.
•	Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG. (1986). Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau. The Lancet, 2(8517), 1211.
•	Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. (1994). Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease. JAMA-Journal of the American Medical Association, 271, 992-998.
•	Stahl SM. (2000). The new cholinesterase inhibitors for Alzheimer's disease part 2: illustrating their mechanisms of action. Journal of Clinical Psychiatry, 61, 813–814.
•	Pandey S, Singh BK. (2020). De-novo Drug Design, Molecular Docking and In-Silico Molecular Prediction of AChEI Analogues through CADD Approaches as Anti-Alzheimer's Agents. Current Computer-Aided Drug Design, 16(1), 54-72.
•	Alzheimer's Association. (2019). 2019 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 15(3), 321-387.
•	Özkan S, Özbabalık D. (2009). Alzheimer Hastalığı'nda Nonfarmakolojik Tedavi Yaklaşımları. Türkiye Klinikleri Journal of Neurology-Special Topics, 2(1), 75-80.
•	Kumar A, Singh A, Ekavali. (2015). A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacological Reports, 67(2), 195-203.
•	Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA. (2009). Pharmacotherapeutic targets in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 13(1), 61-86. doi: 10.1111/j.1582-4934.2008.00595.x.
•	Kuruva CS, Reddy PH. (2017). Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug Discovery Today, 22(2), 223-233.
•	Iraji A, Khoshneviszadeh M, Firuzi O, Khoshneviszadeh M, Edraki N. (2020). Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. Bioorganic Chemistry.
•	Imbimbo BP. (2004). The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opinion on Investigational Drugs, 13(11), 1469-1481.
•	Nevado-Holgado AJ, Lovestone S. (2016). Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. Computational and Structural Biotechnology Journal, 15, 1-7.
•	Bokvist M, Lindström F, Watts A, Gröbner G. (2004). Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. Journal of Molecular Biology, 335(4), 1039-1049.
•	
Liu, D., Xu, Y., Feng, Y., Liu, H., Shen, X., Chen, K., ... Jiang, H. (2006). Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide. Biochemistry, 45(36), 10963-10972.

•	Mancini, R. S., Wang, Y., & Weaver, D. F. (2018). Phenylindanes in Brewed Coffee Inhibit Amyloid-Beta and Tau Aggregation. Frontiers in Neuroscience, 12, 735.

•	Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., & Sampalis, J. (2011). Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Archives of Medical Science, 7(1), 102-111.
•	
van Dyck CH. (2018). Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry, 83(4), 311-319.

•	Götz, J., Ittner, A., & Ittner, L. M. (2012). Tau-targeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 165(5), 1246-1259.


•	Khanna, M. R., Kovalevich, J., Lee, V. M., Trojanowski, J. Q., & Brunden, K. R. (2016). Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer's & Dementia, 12(10), 1051-1065.

•	Brunden, K.R., Lee, V.M., Smith, A.B. 3rd, Trojanowski, J.Q., & Ballatore, C. (2017). Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs. Neurobiology of Disease, 105, 328-335.

•	Khanna, M.R., Kovalevich, J., Lee, V.M., Trojanowski, J.Q., & Brunden, K.R. (2016). Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimer's & Dementia, 12(10), 1051-1065.


•	Noble, W., Jimenez-Sanchez, M., Perez-Nievas, B. G., & Hanger, D. P. (2020). Considerations for future tau-targeted therapeutics: can they deliver? Expert Opinion on Drug Discovery, 15(3), 265-267.
•	
Jadhav, S., Avila, J., Schöll, M., Kovacs, G. G., Kövari, E., Skrabana, R., Evans, L. D., Kontsekova, E., Malawska, B., de Silva, R., Buee, L., & Zilka, N. (2019). A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 7(1), 22.
•	Pedersen, J. T., & Sigurdsson, E. M. (2015). Tau immunotherapy for Alzheimer's disease. Trends in Molecular Medicine, 21(6), 394-402.
•	David, B., Schneider, P., Schäfer, P., Pietruszka, J., & Gohlke, H. (2021). Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and in vitro characterisation. Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 491-496.
•	
Son, M., Park, C., Rampogu, S., Zeb, A., & Lee, K. W. (2019). Discovery of novel acetylcholinesterase inhibitors as potential candidates for the treatment of Alzheimer's disease. International Journal of Molecular Sciences, 20(4), 1000.
•	Brenner, D. E., Kukull, W. A., Stergachis, A., et al. (1994). Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. American Journal of Epidemiology, 140, 262-267.
•	
Henderson, V. W. (1997). The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology, 48, 27-35.
•	
Karaman, Y. (2002). Alzheimer hastalığı ve diğer demanslar. 1. Baskı. Ankara: Lebib Yalkın Matbaası.
•	Terry, D. R., Katzman, R., Bick, L. K., & Sisodia, S. S. (1999). Alzheimer Disease. 2nd ed.
•	
Jick, H., Zomberg, G. L., Jick, S. S., et al. (2000). Statins and the risk of dementia. Lancet, 356, 1627-1631.
•	Wolozin, B., Kellman, W., Rousseau, P., et al. (2000). Decreased prevalence of Alzheimer's disease is associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol, 57, 1439-1443.
•	Haley, R. W., Dietschy, J. M. (2000). Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer's disease? Arch Neurol, 57, 1410-1412.

•	Mahla RS. Stem cells applications in regenerative medicine and disease therapeutics. Int J Cell Biol. 2016;7:6940283.
•	Lyon L. Stem cell therapies in neurology: the good, the bad and the unknown. Brain. 2018;141:e77–e77.

•	Liu XY, Yang LP, Zhao L. (2020). Stem cell therapy for Alzheimer's disease. World J Stem Cells. 12, 787.
•	Ansari SA, Satar R, Perveen A, Ashraf GM. (2017). Current opinion in Alzheimer's disease therapy by nanotechnology-based approaches. Curr Opin Psychiatry. 30(2), 128-135.
•	
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022). Alzheimer's disease drug development pipeline: 2022. Alzheimer's & Dementia (New York, N. Y.), 8(1), e12295.
•	Cummings, J., Lee, G., Nahed, P., Zhong, K., & Fonseca, J. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimer's & Dementia, 9, e12385.
•	Breijyeh, Z., & Karaman, R. (2020). Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules, 25(24), 5789. 
•	
Athar, T., Al Balushi, K., & Khan, S. A. (2021). Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease. Molecular Biology Reports, 48(7), 5629-5645. doi: 10.1007/s11033-021-06512-9. PMID: 34181171.
•	Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimer's & Dementia (New York, N. Y.), 9(2), e12385.

•	Jaturapatporn, D., Isaac, M. G., McCleery, J., & Tabet, N. (2012). Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database of Systematic Reviews, (2).

a few seconds ago